国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

Antiviral drug Remdesivir to be applied in clinical trials Thursday

Source: Xinhua| 2020-02-06 00:17:46|Editor: huaxia

CHINA-HUBEI-WUHAN-ANTIVIRAL DRUG-REMDESIVIR-CONFERENCE (CN)?

Wang Chen (1st R), vice president of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences (CAMS), speaks at a conference in Wuhan, central China's Hubei Province, Feb. 5, 2020. The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday.? (Xinhua/Cheng Min)

BEIJING, Feb. 5 (Xinhua) -- The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday.

The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.

Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug's clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China's Hubei Province.

The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.

A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method.

The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital.

Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS.

   1 2 Next  

KEY WORDS:
EXPLORE XINHUANET
010020070750000000000000011100001387588201
主站蜘蛛池模板: 萨嘎县| 佛学| 阳原县| 家居| 昔阳县| 瑞安市| 佛冈县| 贵州省| 沾化县| 崇义县| 金湖县| 南木林县| 金川县| 张家港市| 西乌| 龙岩市| 祁连县| 吉林市| 昭觉县| 万山特区| 旬阳县| 五原县| 永嘉县| 扬州市| 南乐县| 保靖县| 蒙自县| 长岛县| 翁源县| 昌乐县| 宁晋县| 察哈| 项城市| 望城县| 虎林市| 明水县| 平果县| 长海县| 区。| 民乐县| 成都市|